Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC
2011

LCMR1 and Its Role in Lung Cancer

Sample size: 84 publication Evidence: moderate

Author Information

Author(s): Chen Liangan, Liang Zhixin, Tian Qing, Li Chunsun, Ma Xiuqing, Zhang Yu, Yang Zhen, Wang Ping, Li Yanqin

Primary Institution: Chinese PLA General Hospital

Hypothesis

Is LCMR1 overexpression associated with clinical stage in non-small cell lung cancer (NSCLC)?

Conclusion

LCMR1 is strongly overexpressed in NSCLC and may serve as a biomarker for lung cancer diagnosis and treatment.

Supporting Evidence

  • LCMR1 was found to be significantly overexpressed in NSCLC tissues compared to adjacent normal tissues.
  • Statistical analysis showed a significant association between LCMR1 expression and clinical stage of NSCLC patients.
  • High LCMR1 expression was linked to poor survival rates in patients.

Takeaway

Researchers found that a protein called LCMR1 is much more present in lung cancer tissues than in normal tissues, which could help doctors diagnose and treat lung cancer better.

Methodology

The study used Differential Display-PCR, real-time PCR, and immunohistochemistry to analyze LCMR1 expression in NSCLC tissues.

Limitations

The study had a limited follow-up period and did not find significant associations with other clinicopathologic parameters.

Participant Demographics

Patients diagnosed with NSCLC between 2005 and 2007, aged 32-77 years.

Statistical Information

P-Value

0.026

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-9966-30-18

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication